Sonoma pharmaceuticals, inc. (SNOA)
Income statement / Yearly
Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11
Product

-

-

-

8,077

9,939

7,210

12,897

11,494

8,826

Product licensing fees and royalties

-

-

-

231

3,056

5,513

1,686

359

-

Service

-

-

-

1,061

859

945

869

891

928

Total revenues

18,970

16,658

12,825

9,369

13,854

13,668

15,452

12,744

9,754

Total cost of revenues

10,090

9,348

7,157

-

-

-

-

-

-

Product

-

-

-

5,840

5,908

4,510

3,976

3,254

2,876

Service

-

-

-

881

658

761

733

776

737

Total cost of revenues

-

-

-

6,721

6,566

5,271

4,709

4,030

3,613

Gross profit

8,880

7,310

5,668

2,648

7,288

8,397

10,743

8,714

6,141

Operating expenses
Research and development

1,518

1,575

1,576

1,806

1,533

2,887

2,223

1,981

2,046

Selling, general and administrative

18,620

19,924

17,066

15,556

12,414

11,561

11,894

13,200

11,600

Total operating expenses

20,138

21,499

18,642

17,362

13,947

14,448

14,117

15,181

13,646

Loss from operations

-11,258

-14,189

-12,974

-14,714

-6,659

-6,051

-3,374

-6,467

-7,505

Interest expense

33

40

3

3

3

1,058

1,107

931

406

Interest income

190

258

22

2

1

1

7

4

3

Loss before income taxes

-11,340

-14,278

-12,937

-14,724

-

-

-

-

-

Income tax expense

458

50

-4,268

0

-

-

-

-

-

Loss from continuing operations

-

-

-8,669

-14,724

-

-

-

-

-

Income from discontinued operations (net of tax) (Note 4)

-

-

17,943

4,562

-

-

-

-

-

Impairment loss on long-term investment (See Note 3)

-

-

-

-

-4,650

0

-

-

-

Loss due to change in fair value of common stock (See Note 3)

-

-

-

-

-

-

-

0

-

Gain due to change in fair value of derivative liabilities

-

-

-

-

-

-

-

282

-

(Loss) gain due to change in fair value of derivative instruments

-

-

-

-

-

-

-

-

135

Other expense, net

-

-

-

-

56

81

125

217

175

Gain due to change in fair value of common stock (See Note 10)

-

-

-

-

-

1,357

-1,599

-

-

Gain on deconsolidation of Ruthigen

-

-

-

-

-

11,133

0

-

-

Gain due to change in fair value of derivative liabilities

-

-

-

11

3,164

-1,566

767

-

-

Other income (expense), net

-239

-307

18

-20

-

-

-

-

-

Net loss

-11,798

-14,328

9,274

-10,162

-8,203

3,735

-5,431

-7,329

-7,948

Net (loss) income per share: basic and diluted - Continuing operations

-

-

-2.05

-4.48

-

-

-

-

-

Net (loss) income per share: basic and diluted - Discontinued operations

-

-

4.25

1.39

-

-

-

-

-

Preferred stock deemed dividend

-

-

-

-

-

-

1,062

-

-

Preferred stock deemed dividend

-

-

-

-

-

-

-

0

-

Net income (loss) available to common shareholders

-

-

-

-

-

-

-6,493

-7,329

-

Net income (loss) per share: basic

-

-

-

-

-

0.54

-1.30

-

-

Net income (loss) per share: diluted

-

-

-

-

-

0.54

-1.30

-

-

Weighted-average number of shares used in per share calculations: basic

-

-

-

-

-

6,882

4,977

-

-

Weighted-average number of shares used in per share calculations: diluted

-

-

-

-

-

6,898

4,977

-

-

Net loss per share: basic and diluted

-12.77

-28.49

2.20

-3.09

-0.85

-

-

-1.87

-0.30

Weighted-average number of shares used in per common share calculations: basic and diluted

924

503

4,224

3,289

9

-

-

3

26,374

Other comprehensive loss
Net loss

-11,798

-14,328

9,274

-10,162

-8,203

3,735

-5,431

-7,329

-7,948

Foreign currency translation adjustments

374

203

-324

-347

-438

-78

-

-

-

Comprehensive loss

-12,172

-14,125

8,950

-10,509

-8,641

-

-

-

-

Foreign currency translation adjustments

-

-

-

-

-

-

62

-152

87

Comprehensive loss

-

-

-

-

-

3,657

-5,369

-7,481

-7,861

Product [Member]
Total revenues

17,881

15,663

-

-

-

-

-

-

-

Total cost of revenues

9,334

8,669

-

-

-

-

-

-

-

Service [Member]
Total revenues

1,089

995

-

-

-

-

-

-

-

Total cost of revenues

756

679

-

-

-

-

-

-

-